These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35654000)

  • 1. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer.
    Kwon MR; Chu J; Kook SH; Kim EY
    Clin Imaging; 2022 Sep; 89():1-9. PubMed ID: 35654000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: Factors of radiologic-pathologic discordance.
    Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY; Yoon GY
    Eur J Radiol; 2019 Sep; 118():114-121. PubMed ID: 31439230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
    Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
    Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
    Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
    Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study.
    Kwak L; Santa-Maria C; Di Carlo P; Mullen LA; Myers KS; Oluyemi E; Panigrahi B; Rossi J; Ambinder EB
    Clin Imaging; 2023 Sep; 101():105-112. PubMed ID: 37327550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
    Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
    Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment MRI features associated with diagnostic accuracy of post-treatment MRI after neoadjuvant chemotherapy.
    Eun NL; Gweon HM; Son EJ; Youk JH; Kim JA
    Clin Radiol; 2018 Jul; 73(7):676.e9-676.e14. PubMed ID: 29567270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
    Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
    J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-operative MRI in evaluating pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer: a study focused on influencing factors of baseline clinical-pathological and imaging features.
    Hu Q; Hu Y; Ai H; Xia L; Liu R; Ai T
    Front Oncol; 2024; 14():1366613. PubMed ID: 38826784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
    van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
    Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
    Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
    Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
    Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
    Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Epidermal Growth Factor 2-positive Breast Cancer with Mammographic Microcalcification: Relationship to Pathologic Complete Response after Neoadjuvant Chemotherapy.
    Mazari FAK; Sharma N; Dodwell D; Horgan K
    Radiology; 2018 Aug; 288(2):366-374. PubMed ID: 29786482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating persistent T1-weighted lesions without concurrent abnormal enhancement on breast MRI in neoadjuvant chemotherapy patients: implications for complete pathological response.
    Goulam-Houssein S; Ye XY; Fleming R; Au F; Kulkarni S; Ghai S; Amitai Y; Reedijk M; Freitas V
    Eur Radiol; 2024 Oct; 34(10):6273-6282. PubMed ID: 38491128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of
    Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
    AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
    [No Abstract]   [Full Text] [Related]  

  • 19. MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.
    Sener SF; Sargent RE; Lee C; Manchandia T; Le-Tran V; Olimpiadi Y; Zaremba N; Alabd A; Nelson M; Lang JE
    J Surg Oncol; 2019 Nov; 120(6):903-910. PubMed ID: 31400007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
    Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
    Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.